Dexcom G7 15-Day System: Expanding the Impact of Continuous Glucose Monitoring
The landscape of diabetes management is shifting toward longer wear times and more personalized data. Dexcom has recently accelerated this transition with the full U.S. Availability of the Dexcom G7 15-day system, a significant evolution in continuous glucose monitoring (CGM) technology. This modern system doesn’t just extend the time a sensor stays on the body; it’s backed by new clinical data showing meaningful health improvements across different types of diabetes.
- The Dexcom G7 15-day sensor is now fully available in the U.S.
- New registry data shows long-term G7 use helps people with type 2 diabetes (non-insulin treated) lower A1C and manage weight.
- CGM initiation is linked to fewer DKA-related hospitalizations and ER visits for those with type 1 diabetes.
- Dexcom is introducing “Smart Basal,” a new optimizer for basal insulin dosing.
- The company has announced the phase-out of the older G6 system.
The Shift to the G7 15-Day System
For many users, the frequency of sensor changes is a primary pain point. The launch of the Dexcom G7 15-day system addresses this by extending the wear duration, reducing the maintenance burden on the patient. As Dexcom moves forward with this innovation, the company is also beginning the phase-out of the G6 sensor to streamline its offerings and ensure users have access to the most current technology.
Clinical Breakthroughs for Type 2 Diabetes
While CGMs were traditionally associated with insulin-dependent patients, new data presented at ATTD 2026 highlights the benefits for a broader population. Registry data specifically focused on people with type 2 diabetes who are not on insulin therapy.
A1C and Weight Management
Real-world impact data from U.S. Primary care evidence demonstrates that after one year of using the Dexcom G7, non-insulin-treated type 2 diabetes patients saw significant improvements in:
- HbA1C Levels: Long-term use supports a reduction in A1C, indicating better overall glucose control.
- Weight Management: The data suggests a positive correlation between CGM use and weight management in this population.
Optimizing Insulin Therapy with Smart Basal
For those with type 2 diabetes who are starting or optimizing basal insulin, Dexcom is introducing Smart Basal. This basal insulin dosing optimizer has undergone a feasibility study that supports its safety and efficacy, helping clinicians and patients fine-tune insulin delivery more accurately.
Improving Outcomes for Type 1 Diabetes
The impact of CGM technology remains critical for those with type 1 diabetes. Recent claims data highlights a strong association between the initiation of CGM use and a reduction in critical medical emergencies. Specifically, the data shows a decrease in:
- Emergency room visits related to diabetic ketoacidosis (DKA).
- DKA-related hospitalizations.
By providing real-time glucose visibility, the system allows for faster interventions, preventing glucose levels from reaching dangerous thresholds.
Comparing the Evolution of Dexcom CGM
| Feature | Dexcom G6 | Dexcom G7 (15-Day) |
|---|---|---|
| Status | Being phased out | Fully available in U.S. |
| Wear Duration | Standard | Extended 15-day wear |
| Key Innovations | Foundation CGM | Smart Basal optimizer; improved registry outcomes |
Frequently Asked Questions
Who benefits most from the G7 15-day system?
While it benefits all CGM users by reducing sensor changes, registry data specifically highlights significant A1C and weight management benefits for people with type 2 diabetes who aren’t using insulin, as well as reduced DKA risks for those with type 1 diabetes.
What is Smart Basal?
Smart Basal is a new dosing optimizer designed to support people with type 2 diabetes safely and effectively start or optimize their basal insulin therapy.
Is the Dexcom G6 still available?
Dexcom has announced a phase-out of the G6 as the G7 15-day system becomes the primary offering.
The Future of Glucose Monitoring
The transition to the G7 15-day system and the introduction of tools like Smart Basal signal a move toward more proactive, data-driven diabetes care. By expanding the proven benefits of CGM to non-insulin-treated type 2 populations and reducing acute complications in type 1 patients, these innovations are lowering the barriers to long-term health management.